Santen Pharmaceutical Adjusts Valuation Amid Mixed Financial Performance Indicators

Santen Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation score, indicating a more favorable assessment of its financial metrics. The stock's P/E ratio stands at 18, while the Price to Book Value is recorded at 1.92. Additionally, the EV to EBIT ratio is noted at 12.58, and the EV to EBITDA ratio is 8.73. The company also shows an EV to Sales ratio of 1.80 and a PEG ratio of 1.42. Notably, Santen's Return on Capital Employed (ROCE) is at 16.00%, and its Return on Equity (ROE) is 10.76%, reflecting its efficiency in generating returns for shareholders. Despite these metrics, the company has faced challenges, including a low average ROE of 6.50% and modest operating profit growth of 1.43% annually over the past five years. The latest quarter's performance has shown flat results, with operating cash flow at JPY 41,411 million and an inventory turnover ratio of 2.42 times. For those interested in tracking Santen Pharmaceutical Co., Ltd.'s evolving financial landscape, further insights can be found here: Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.